White Paper
Mind Matters: Shining the spotlight on Alzheimer's Disease in India
Oct 24, 2025

Mind Matters: Shining the spotlight on Alzheimer's Disease in India explores the rising prevalence of Alzheimer's disease in India, currently affecting 8.8 million people over age 60. It highlights diagnostic and management practices, comparing India's evolving healthcare infrastructure with Western standards. The paper discusses challenges in rural diagnosis, the role of PET scans, and the use of both modern and traditional treatments, including Ayurvedic herbs. It emphasizes the growing availability of disease-modifying therapies like Lecanemab and Donanemab, and the importance of early diagnosis—supported by innovations such as the Lumipulse blood test, now being locally manufactured in India.

The paper also outlines government initiatives like the National Mental Health Program, Ayushman Bharat Scheme, and Atal Vayo Abhyuday Yojna, aimed at improving elderly care and dementia management. India's potential in Alzheimer's clinical research is underscored by its large, genetically diverse, and treatment-naive population. Studies like TLSA and SANSCOG are paving the way for deeper epidemiological insights. The paper calls for more region-specific data, cost analyses, and caregiver support frameworks, noting the unique familial structures in India. Finally, it advocates for India's inclusion in global research consortia and highlights regulatory progress, such as the DCGI's push for local Phase III trials. With a growing pharmaceutical industry and English-speaking healthcare professionals, India is positioned to become a key player in Alzheimer's research and care.

Contact Us